Fresenius has completed the acquisition of the remaining 45% stake in mAbxience for up to €750 million, including a €50 million conditional payment. The transaction closed on September 30, 2026 and was announced on October 1, 2026. It was financed from existing liquidity and operating cash flow, with no new financing raised. Fresenius shares rose 2.21% on October 16, 2026.
What mAbxience is
mAbxience is a biosimilars development and manufacturing platform: more than €320 million in revenue in FY2025, three production sites, over 1,300 employees, four marketed products, and eight development candidates. In plain terms, it is the kind of integrated platform — R&D plus large-scale biologics manufacturing plus a commercial portfolio — that takes a decade and enormous capital to build from scratch, which is exactly why acquiring it outright is cheaper than replicating it.
The biosimilars market: patent cliffs as opportunity
Biosimilars are near-copies of biologic drugs (complex medicines grown in living cells, such as monoclonal antibodies) whose patents have expired. Unlike simple chemical generics, biosimilars require sophisticated cell-line development, clinical comparability studies, and specialized manufacturing — barriers that keep competition limited and margins healthier than in traditional generics.
The industry is riding a wave of patent cliffs: blockbuster biologics worth tens of billions in annual sales are losing exclusivity through the late 2020s, opening the door for biosimilar challengers. Each cliff creates a land grab — the first biosimilars to market in each molecule capture disproportionate share — so owning a ready-made platform with marketed products and a pipeline of eight candidates positions Fresenius to compete across multiple upcoming cliffs rather than betting on a single drug.
Why pharma is consolidating manufacturing platforms
Biologics manufacturing is brutally capital-intensive: sterile fill-finish lines, bioreactors at scale, and quality systems that satisfy regulators on multiple continents. Few companies can justify building three production sites organically. Consolidation is therefore structural:
- Scale economics. Each additional product run through existing plants improves utilization and margins.
- Regulatory moats. Approved, inspected facilities are scarce assets — buying them acquires years of regulatory history that cannot be fast-tracked.
- Portfolio breadth. Payers and hospital systems prefer suppliers that can offer multiple biosimilars, making a four-marketed-product portfolio plus pipeline more valuable inside a large healthcare group than standalone.
Buyout-of-minority deal mechanics
Fresenius already owned 55% of mAbxience; this deal buys out the remaining 45%. Minority buyouts are among the cleanest transactions in M&A: the buyer already controls the company, knows the operations intimately, and faces no bidding competition — the main negotiation is price.
Two features of this deal are worth noting. First, the €50 million conditional payment — a form of earnout or contingent consideration, paid only if agreed milestones (typically pipeline progress, regulatory approvals, or revenue targets) are met. It bridges valuation gaps by letting the seller participate in upside the buyer isn't willing to pay for upfront. Second, financing from existing liquidity and operating cash flow with no new financing signals balance-sheet strength: Fresenius could absorb a €750 million outlay without issuing debt or equity, avoiding both interest costs and shareholder dilution.
The operating backdrop supports the confidence. In Q2 2026, Fresenius reported revenue of €5.864 billion (+6% year over year), EBIT of €719 million (+10% in constant currency), and a 12.3% margin — and raised its full-year constant-currency core EPS growth guidance to 10–15%.
Why it matters for founders and investors
For biotech founders, the mAbxience buyout shows that integrated platforms — discovery through manufacturing — command strategic premiums, and that minority-stake structures can be a viable path to a full exit: prove the platform as a partner, then sell the rest. For investors, it confirms the biosimilars patent-cliff trade is moving from thesis to consolidation, with well-capitalized strategics willing to pay up for derisked manufacturing capacity.
Angeled.com connects founders with investors. Sources: ad-hoc-news.de (Oct 16, 2026).
Read Next
Inovalon to Acquire DrFirst, Uniting Healthcare Data With Prescribing Workflows
Oura to Acquire Counsel Health for $625 Million, Putting a Doctor Behind the Ring
Anthropic Files Updated IPO Prospectus Aiming at a $1.4 Trillion Valuation
Archrock to Acquire HiVolt Energy for Up to $450 Million
Barrick Mining Files to Spin Off and List Its North American Gold Business
What a $1.4 Trillion Anthropic IPO Would Mean for Founders



